

ASX Release
ASX Code: MEM

28 February 2025

Extension of Convertible Notes

Memphasys Limited (ASX: MEM) (Company) announces that it continues to receive ongoing support from Peters Investments Pty Ltd who has agreed to extend the maturity date for its Convertible Notes (**Notes**) (with an aggregate face value of \$3m, plus capitalised facilitation fees and accrued interest) from 30 June 2025 to 31 December 2025.

As part of the agreed extension:

- all interest accrued on the Notes from 1 January 2025 to 30 June 2025 will be paid in cash by the Company on 30 June 2025; and
- all interest accrued between 1 July 2025 and 31 December 2025 will be paid in cash on 31 December 2025.

The Board expresses its thanks to Peters Investments Pty Ltd for the continued support it has shown the Company.

Approved for release by the Board.

ENDS

For further information, please contact:

Dr David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.